# Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/oral-rimegepant-for-preventive-treatment-of-migraine-a-phase-2-3-randomised/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert Croop,Richard B. Lipton,David Kudrow,David Stock,Lisa Kamen,Charles M. Conway,Elyse Stock,Vladimir Coric,Peter J. Goadsby |
| Citations | 354 |
| DOI | 10.1016/s0140-6736(20)32544-7 |
| Fields | Medicine,Neuroscience |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3111685616 |
| PMID | 33338437 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Vladimir Coric](https://scholariq.org/researchers/vladimir-coric/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)

## Paper topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Neurological Disorders and Treatments](https://scholariq.org/topics/neurological-disorders-and-treatments-2/)
- [Traumatic Brain Injury and Neurovascular Disturbances](https://scholariq.org/topics/traumatic-brain-injury-and-neurovascular-disturbances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.